Cargando…

Tu1257: AUTOIMMUNE HEPATITIS FOLLOWING COVID-19 VACCINATION: A SYSTEMATIC REVIEW OF THE LITERATURE

Detalles Bibliográficos
Autores principales:	Chow, Kenneth W., Pham, Nguyen V., Ibrahim, Brittney M., Hong, Kimberly, Saab, Sammy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AASLD Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212459/ http://dx.doi.org/10.1016/S0016-5085(22)63678-3

Ejemplares similares

Tu1254: SARS-COV-2 VACCINATION HESITANCY AND RISK OF DISEASE FLARE ARE BOTH LOW AMONG AN AUTOIMMUNE HEPATITIS PATIENT COHORT
por: Chalasani, Sai, et al.
Publicado: (2022)

Tu1261: IMPACT OF THE COVID-19 PANDEMIC ON THE EPIDEMIOLOGY OF ALCOHOL-ASSOCIATED HEPATITIS
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Tu1270: SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN LIVER TRANSPLANT PATIENTS
por: Toapanta-Yanchapaxi, Liz, et al.
Publicado: (2022)

Su318 PATTERNS OF LIVER TRANSPLANTATION EVALUATIONS FOR HOSPITALIZED ADULTS WITH ACUTE ALCOHOLIC HEPATITIS DURING COVID-19: A SINGLE CENTER STUDY
por: Bangaru, Saroja, et al.
Publicado: (2021)

Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

Tu1255: SAFETY AND EFFICACY OF COVID-19 VACCINES IN PATIENTS WITH CIRRHOSIS: A CROSS SECTIONAL, OBSERVATIONAL STUDY
por: Singh, Virendra, et al.
Publicado: (2022)

Tu1260: IMPACT OF COVID-19 ON PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS
por: Moga, Tudor V., et al.
Publicado: (2022)

Tu1268: LONGITUDINAL ASSESSMENT OF SEROLOGICAL RESPONSE AFTER THREE DOSES OF SARS-COV-2 MRNA VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Gandle, Cassandra, et al.
Publicado: (2022)

Tu1263: DOES COVID 19 VACCINATION PREVENT LIVER INJURY? – A LONGITUDINAL COMPARISON BETWEEN COVID 19 VACCINATED PATIENTS AND COVID 19 UNVACCINATED PATIENTS.
por: Rammohan, Rajmohan, et al.
Publicado: (2022)

Tu1259: CLINICAL FEATURES AND CHARACTERISTIC OF CHOLANGIOPATHY AFTER SEVERE COVID-19
por: Li, Tian, et al.
Publicado: (2022)

Tu1265: LIVER INJURY IN HOSPITALIZED COVID-19 PATIENTS TREATED WITH TOCILIZUMAB
por: Kalligeros, Markos, et al.
Publicado: (2022)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Tu1266: VARIABLE IMPACT OF COVID-19 PANDEMIC ON HOSPITALIZATION FOR ALCOHOL-ASSOCIATED LIVER DISEASE.
por: Lee, Tai-Ping, et al.
Publicado: (2022)

Tu1256: METFORMIN USE IS ASSOCIATED WITH LESS FREQUENT SEVERE LIVER INJURY UPON HOSPITAL ADMISSIN WITH COVID-19
por: Kuntzen, Christian, et al.
Publicado: (2022)

Tu1271: T-BOX TRANSCRIPTION FACTOR 19 PROMOTES HEPATOCELLULAR CARCINOMA METASTASIS THROUGH UPREGULATING EGFR AND RAC1
por: Xia, Limin
Publicado: (2022)

Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature
por: Chow, Kenneth W., et al.
Publicado: (2022)

Tu1267: TELEMEDICINE DURING COVID-19 PANDEMIC IS AN ACCEPTABLE MODALITY FOR LIVER CARE DELIVERY IN VULNERABLE POPULATIONS WITH FATTY LIVER DISEASE
por: Khalili, Mandana, et al.
Publicado: (2022)

Tu1262: IN-HOSPITAL CASE FATALITY RATE DUE TO MODERATE-TO-SEVERE COVID-19 IN PATIENTS WITH CIRRHOSIS: A MULTICENTER COHORT STUDY
por: Astudillo-Romero, Beatriz, et al.
Publicado: (2022)

Tu1264: PATIENTS WITH CIRRHOSIS EXPERIENCE HIGHER ICU MORTALITY COMPARED TO NON-CIRRHOTIC PATIENTS WHICH CONTINUED WITH OR WITHOUT COVID-19 DESPITE CONTROLLING FOR ORGAN FAILURE SEVERITY
por: Park, Dan, et al.
Publicado: (2022)

Su322 SEVERE CHOLESTATIC HEPATITIS SECONDARY TO SARS-COV-2
por: Lindholm, Christopher R., et al.
Publicado: (2021)

Su325 HEPATIC STEATOSIS MAY LEAD TO WORSE OUTCOMES IN PATIENTS WITH LIVER INJURY AND COVID-19
por: Shaikh, Danial H., et al.
Publicado: (2021)

310 Ribavirin coupled to hemoglobin protects against viral hepatitis induced by the corona virus MHV-3 in mice
por: Levy, Gary A., et al.
Publicado: (2003)

782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

Su320 A RETROSPECTIVE ANALYSIS OF OUTCOMES AMONGST COVID-19 PATIENTS WITH ACUTE HEPATITIS RECEIVING N-ACETYLCYSTEINE THERAPY IN A SAFETY NET HOSPITAL
por: Pellegrini, James R., et al.
Publicado: (2021)

Sa1389: LESSONS FROM HEPATITIS C TREATMENT DURING THE COVID-19 PANDEMIC: DECREASED RESOURCE UTILIZATION LEADS TO SIMILAR EFFICACY IN BRITISH COLUMBIA, CANADA
por: Jiang, Shirley X., et al.
Publicado: (2022)

Su316 INCREASED DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN HOSPITALIZED PATIENTS WITH ALCOHOL RELATED HEPATITIS AFTER THE COVID-19 OUTBREAK: A GLOBAL MULTI-CENTER PROPENSITY MATCHED ANALYSIS.
por: Perisetti, Abhilash, et al.
Publicado: (2021)

783: INCIDENCE AND OUTCOMES OF COVID-19 IN POST-LIVER TRANSPLANT RECIPIENTS AFTER COVID-19 VACCINATION IN A LARGE INTEGRATED HEALTHCARE SYSTEM
por: Tien, Andy, et al.
Publicado: (2022)

EP1197: REDUCTION IN SPLEEN SIZE FOLLOWING SUSTAINED VIROLOGIC RESPONSE PREDICTS DECREASED DECOMEPENSATION AND LOWER MORTALITY IN PATIENTS WITH HCV CIRRHOSIS
por: Prakash, Shahana, et al.
Publicado: (2022)

Mo1336: PREVALENCE AND MORTALITY OF ALCOHOL-RELATED LIVER DISEASES DURING COVID-19 PANDEMIC
por: Yeo, Yee Hui, et al.
Publicado: (2022)

Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
por: AlEid, Ahmad, et al.
Publicado: (2022)

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

437 A TAILORED PROGRAM FOR SCREENING, IMPROVED ACCESS TO CARE, AND PRIORITIZATION OF TREATMENT FOR PWUD WITH CHRONIC HCV INFECTION.
por: Mangia, Alessandra, et al.
Publicado: (2021)

13 CHEMOPREVENTIVE EFFECT OF STATIN ON HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS WITH CIRRHOSIS
por: Al-Yaman, Wael A., et al.
Publicado: (2021)

7 A RETROSPECTIVE ANALYSIS OF COVID-19 INFECTED PATIENTS WITH ACUTE LIVER FAILURE IN A SAFETY NET HOSPITAL
por: Pellegrini, James R., et al.
Publicado: (2021)

8 PREDICTORS OF OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
por: Sandhu, Sunny, et al.
Publicado: (2021)

12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY
por: Chen, Shu-Ling, et al.
Publicado: (2021)

9 ELEVATED LIVER ENZYMES PORTENDS A HIGHER RATE OF COMPLICATIONS AND DEATH IN ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
por: Currier, Emily E., et al.
Publicado: (2021)

6 CIRRHOSIS IS ASSOCIATED WITH SIGNIFICANTLY WORSENED CLINICAL OUTCOMES OF COVID-19 INFECTION IN A RETROSPECTIVE ANALYSIS OF 23,474 PATIENTS ACROSS 143 HOSPITALS
por: Hwang, Andrew W., et al.
Publicado: (2021)

435 INCIDENCE AND MORTALITY OF COVID-19 IN POST-LIVER TRANSPLANT PATIENTS IN A LARGE INTEGRATED HEALTHCARE SYSTEM
por: Tien, Andy, et al.
Publicado: (2021)

11 TRENDS IN ALCOHOL RELATED LIVER DISEASE DURING THE SARS-COV 2 PANDEMIC: REAL-TIME ANALYSIS OF SYSTEMWIDE DATA TRENDS USING EPIC SLICERDICER™.
por: Roark, Travis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7r5qefahc52f3hja44afkr5pcv